Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06601244

Pharmacokinetic Study in the Biliary Complications During Liver Transplantation

Sponsor: University Hospital, Grenoble

View on ClinicalTrials.gov

Summary

Liver transplantation is the last treatment for severe liver diseases such as advanced cirrhosis or fulminant hepatitis. This is a heavy treatment can be associated with numerous complications, particularly biliary ones. The management of biliary complications is mixed, combining endoscopic treatment with biliary protheses and antibiotics. A cohort study carried out at the Grenoble Alpes University Hospital showed a high prevalence of Enterococcus Faecium during these biliary complications. This epidemiology complicates the treatment, because it presents a natural resistance to cephalosporins and penicillin (60% of resistance to amoxicillin in Grenoble hospital), the first line treatment for biliary infection. Antibiotic used to treat this infection can be DALBAVANCIN, which are compatible with outpatient follow-up. Although the results are interesting in term of efficacy, no study has investigated the biliary diffusion of this antibiotic.

Official title: Pharmacokinetic Study of DALBAVANCINE in the Treatment of Biliary Complications During Liver Transplantation

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

10

Start Date

2024-09-15

Completion Date

2025-09-30

Last Updated

2024-09-19

Healthy Volunteers

No

Interventions

OTHER

Pharmacokinetic

Biliary and blood concentration of the DALBAVANCINE

Locations (1)

University Hospital Of Grenoble

Grenoble, France